InnoCare Pharma Limited (9969.HK)
9969.HK Stock Price Chart
Explore InnoCare Pharma Limited interactive price chart. Choose custom timeframes to analyze 9969.HK price movements and trends.
9969.HK Company Profile
Discover essential business fundamentals and corporate details for InnoCare Pharma Limited (9969.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Mar 2020
Employees
1.09K
Website
https://www.innocarepharma.comCEO
Jisong Cui
Description
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
9969.HK Financial Timeline
Browse a chronological timeline of InnoCare Pharma Limited corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 19 Aug 2025
Revenue for the quarter reached $383.53M , beating expectations by +0.24%.
Earnings released on 13 May 2025
EPS came in at $0.01 , while revenue for the quarter reached $408.77M , beating expectations by +25.05%.
Earnings released on 27 Mar 2025
EPS came in at -$0.11 , while revenue for the quarter reached $331.59M , beating expectations by +13.10%.
Earnings released on 11 Nov 2024
EPS came in at -$0.01 , while revenue for the quarter reached $307.64M .
Earnings released on 20 Aug 2024
EPS came in at -$0.09 , while revenue for the quarter reached $272.68M .
Earnings released on 13 May 2024
EPS came in at -$0.09 , while revenue for the quarter reached $179.41M .
Earnings released on 28 Mar 2024
EPS came in at -$0.07 surpassing the estimated -$0.22 by +70.10%, while revenue for the quarter reached $222.66M , missing expectations by -77.39%.
Earnings released on 30 Sept 2023
EPS came in at -$0.07 , while revenue for the quarter reached $171.41M .
Earnings released on 30 Jun 2023
EPS came in at -$0.21 surpassing the estimated -$0.22 by +3.69%, while revenue for the quarter reached $203.48M .
Earnings released on 31 Mar 2023
EPS came in at -$0.01 , while revenue for the quarter reached $216.18M .
Earnings released on 31 Dec 2022
EPS came in at -$0.04 surpassing the estimated -$0.30 by +88.17%, while revenue for the quarter reached $209.32M , beating expectations by +16.47%.
Earnings released on 30 Sept 2022
EPS came in at -$0.30 , while revenue for the quarter reached $214.93M .
Earnings released on 30 Jun 2022
EPS came in at -$0.28 falling short of the estimated -$0.10 by -183.11%, while revenue for the quarter reached $148.48M , missing expectations by -15.25%.
Earnings released on 31 Mar 2022
EPS came in at -$0.10 , while revenue for the quarter reached $146.81M .
Earnings released on 23 Mar 2022
EPS came in at $0.25 falling short of the estimated $0.48 by -47.02%, while revenue for the quarter reached $1.06B , beating expectations by +12.58%.
Earnings released on 31 Dec 2021
EPS came in at -$0.12 , while revenue for the quarter reached $75.42M .
Earnings released on 30 Jun 2021
EPS came in at -$0.09 , while revenue for the quarter reached $61.03M .
Earnings released on 31 Mar 2021
EPS came in at -$0.09 surpassing the estimated -$0.22 by +56.85%, while revenue for the quarter reached $60.19M , missing expectations by -45.05%.
Earnings released on 31 Dec 2020
EPS came in at -$0.03 , while revenue for the quarter reached $365.79K .
Earnings released on 30 Sept 2020
EPS came in at -$0.03 surpassing the estimated -$0.25 by +88.83%, while revenue for the quarter reached $351.19K , missing expectations by -40.64%.
9969.HK Stock Performance
Access detailed 9969.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.